文献速递妇科

晚期子宫内膜癌辅助盆腔放疗联合化疗对比单纯化疗的生存获益界定

Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
PubMed 文献 · Gynecol Oncol · 2019-06-28

基于美国国家癌症数据库2004至2016年FIGO III-IVA期子宫内膜癌行子宫全切及辅助多药化疗的13270例患者,分析盆腔体外放疗对比单纯化疗的总生存。单因素分析中放疗在子宫内膜样和非子宫内膜样队列分别与5年绝对生存率提高5%和9%相关(P<0.0001)。多因素分析显示IIIC期(尤其IIIC2)子宫内膜样及IIIB、IIIC期非子宫内膜样患者从放疗获益显著。

要点

  • III-IVA期子宫内膜癌接受盆腔放疗与生存获益因分期和病理类型而异
  • 单因素分析放疗在子宫内膜样和非子宫内膜样队列分别与5年生存提高5%和9%相关
  • IIIC2期子宫内膜样及IIIB-C期非子宫内膜样患者可能最受益于盆腔放疗

核心结论

  • III-IVA期子宫内膜癌在接受化疗基础上加用盆腔放疗的获益在人群中呈异质性,IIIC2期子宫内膜样及IIIB-C期非子宫内膜样患者可能最可能获益。

研究设计与样本

  • 基于美国国家癌症数据库的队列研究,纳入2004至2016年FIGO III-IVA期子宫内膜癌、至少行子宫全切及辅助多药化疗的患者13270例。

主要发现

  • 全队列中40%接受盆腔体外放疗;病理为纯子宫内膜样62%、浆液性/透明细胞或混合38%;分期IIIA占22.6%、IIIB占4.7%、IIIC占71.2%、IVA占1.5%。
  • 单因素分析中,放疗在子宫内膜样队列与非子宫内膜样队列分别与5年绝对生存率提高5%和9%相关(P<0.0001)。
  • 按分期和病理分层多因素分析,放疗显著获益者为IIIC期(具体为IIIC2)子宫内膜样(校正HR 0.73,P=0.01)、IIIB期非子宫内膜样(校正HR 0.52,P=0.01)和IIIC期非子宫内膜样(校正HR 0.79,P<0.0001)。
  • 淋巴结阳性患者中放疗的获益在行更广泛淋巴结清扫者中持续存在。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine which patients with locoregionally advanced endometrial cancer may benefit from pelvic external beam radiotherapy (EBRT) in addition to chemotherapy compared to chemotherapy alone. METHODS: Patients with FIGO stages III-IVA endometrial carcinoma between 2004 and 2016 who underwent at least total hysterectomy and adjuvant multiagent chemotherapy were identified in the National Cancer Database. The primary outcome was overall survival according to receipt of pelvic EBRT, analyzed using the Kaplan-Meier method and Cox multivariable regression. RESULTS: In total, 13,270 patients were identified (62% pure endometrioid, 38% serous/clear cell or mixed histology; 22.6% stage IIIA, 4.7% stage IIIB, 71.2% stage IIIC, 1.5% stage IVA), of whom 40% received pelvic EBRT. In univariable analysis, EBRT was associated with absolute 5-year survival increases of 5% and 9% in the endometrioid and non-endometrioid cohorts, respectively (P < 0.0001). In multivariable analyses stratified by stage and histology, patients with a significant benefit from EBRT were stage IIIC (specifically IIIC2) endometrioid (adjusted hazard ratio [HR] 0.73, P = 0.01) and stages IIIB and IIIC non-endometrioid (adjusted HR 0.52, P = 0.01 and adjusted HR 0.79, P < 0.0001). The benefit of EBRT in node-positive patients persisted in those who underwent more extensive lymphadenectomy. CONCLUSIONS: Stages III-IVA endometrial cancer comprised a heterogeneous population with respect to the added benefit of radiotherapy compared to chemotherapy alone. Patients with stage IIIC2 endometrioid and stages IIIB-C non-endometrioid cancer may be most likely to benefit from pelvic EBRT.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Xiang M, English DP, Kidd EA, et al. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma. Gynecol Oncol. 2019. PMID: 31257010. doi:10.1016/j.ygyno.2019.06.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。